FAST NEWS: Henlius Lung Cancer Drug Gets ‘Orphan’ Status in Europe
The latest: Shanghai Henlius Biotech Inc. (2696.HK) said on Thursday its self-developed small cell lung cancer drug Hansizhuang has been granted orphan drug status by the European Commission (EC).Looking up:…
RELATED ARTICLES
-
Shunned by investors, Henlius hangs up on its Hong Kong listing
2696.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
1672.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
Discover hidden China stock gems in our weekly newsletter